How Does It Work for MASH? Rezdiffra belongs to a class of medicines called thyroid hormone receptor-beta (THR-β) agonists. In the liver, Rezdiffra attaches to the THR-β receptors. This ...

The results further emphasize the efficacy of their thyroid hormone receptor (THR)-β agonist, Rezdiffra, in treating NASH. Rezdiffra is an innovative, once-daily medication that targets key ...

Rezdiffra (resmetirom) is a prescription drug used to help treat a specific kind of liver disease in certain situations. Rezdiffra comes as an oral tablet. Rezdiffra is used to treat nonalcoholic ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

The company’s top line comprises only its product revenues. Madrigal’s commercial portfolio has one marketed drug, Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist.

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...